2021 年的肝癌:全球疾病负担研究

IF 26.8 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
En Ying Tan, Pojsakorn Danpanichkul, Jie Ning Yong, Zhenning Yu, Darren Jun Hao Tan, Wen Hui Lim, Benjamin Koh, Ryan Yan Zhe Lim, Ethan Kai Jun Tham, Kartik Mitra, Asahiro Morishita, Yao-Chun Hsu, Ju Dong Yang, Hirokazu Takahashi, Ming-Hua Zheng, Atsushi Nakajima, Cheng Han Ng, Karn Wijarnpreecha, Mark D. Muthiah, Amit G. Singal, Daniel Q. Huang
{"title":"2021 年的肝癌:全球疾病负担研究","authors":"En Ying Tan, Pojsakorn Danpanichkul, Jie Ning Yong, Zhenning Yu, Darren Jun Hao Tan, Wen Hui Lim, Benjamin Koh, Ryan Yan Zhe Lim, Ethan Kai Jun Tham, Kartik Mitra, Asahiro Morishita, Yao-Chun Hsu, Ju Dong Yang, Hirokazu Takahashi, Ming-Hua Zheng, Atsushi Nakajima, Cheng Han Ng, Karn Wijarnpreecha, Mark D. Muthiah, Amit G. Singal, Daniel Q. Huang","doi":"10.1016/j.jhep.2024.10.031","DOIUrl":null,"url":null,"abstract":"<h3>Background &amp; Aims</h3>The epidemiology of adult primary liver cancer continues to evolve, related to the increasing prevalence of metabolic disease, rising alcohol consumption, advancements in vaccination for hepatitis B (HBV), and antiviral therapy for hepatitis C (HCV). Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021.<h3>Methods</h3>Utilizing the methodological framework of the Global Burden of Disease Study 2021, we analyzed global and regional temporal trends in incidence and mortality, and the contributions of various etiologies of liver disease.<h3>Results</h3>In 2021, there were an estimated 529202 incident cases and 483875 deaths related to liver cancer. From 2010 to 2021, global liver cancer incident cases and deaths increased by 26% and 25%, respectively. Global age-standardized incidence rates (ASIRs) and death rates (ASDRs) for liver cancer declined but rose in the Americas and Southeast Asia. HBV remained the dominant cause of global incident liver cancer cases and deaths. Metabolic dysfunction-associated steatotic liver disease (MASLD) was the only etiology of liver cancer with rising ASIRs and ASDRs. By contrast, ASIRs and ASDRs remained stable for alcohol-related liver cancer, and declined for HBV- and HCV-related liver cancer.<h3>Conclusions</h3>While age-adjusted incidence and deaths from liver cancer have started to decline, the absolute number of incident cases and deaths continues to increase. Population growth and aging contribute to the observed disconnect in the temporal trends of absolute cases and rates. Disparities remain, and MASLD-related liver cancer continues to surge.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":26.8000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Liver Cancer in 2021: Global Burden of Disease Study\",\"authors\":\"En Ying Tan, Pojsakorn Danpanichkul, Jie Ning Yong, Zhenning Yu, Darren Jun Hao Tan, Wen Hui Lim, Benjamin Koh, Ryan Yan Zhe Lim, Ethan Kai Jun Tham, Kartik Mitra, Asahiro Morishita, Yao-Chun Hsu, Ju Dong Yang, Hirokazu Takahashi, Ming-Hua Zheng, Atsushi Nakajima, Cheng Han Ng, Karn Wijarnpreecha, Mark D. Muthiah, Amit G. Singal, Daniel Q. Huang\",\"doi\":\"10.1016/j.jhep.2024.10.031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3>Background &amp; Aims</h3>The epidemiology of adult primary liver cancer continues to evolve, related to the increasing prevalence of metabolic disease, rising alcohol consumption, advancements in vaccination for hepatitis B (HBV), and antiviral therapy for hepatitis C (HCV). Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021.<h3>Methods</h3>Utilizing the methodological framework of the Global Burden of Disease Study 2021, we analyzed global and regional temporal trends in incidence and mortality, and the contributions of various etiologies of liver disease.<h3>Results</h3>In 2021, there were an estimated 529202 incident cases and 483875 deaths related to liver cancer. From 2010 to 2021, global liver cancer incident cases and deaths increased by 26% and 25%, respectively. Global age-standardized incidence rates (ASIRs) and death rates (ASDRs) for liver cancer declined but rose in the Americas and Southeast Asia. HBV remained the dominant cause of global incident liver cancer cases and deaths. Metabolic dysfunction-associated steatotic liver disease (MASLD) was the only etiology of liver cancer with rising ASIRs and ASDRs. By contrast, ASIRs and ASDRs remained stable for alcohol-related liver cancer, and declined for HBV- and HCV-related liver cancer.<h3>Conclusions</h3>While age-adjusted incidence and deaths from liver cancer have started to decline, the absolute number of incident cases and deaths continues to increase. Population growth and aging contribute to the observed disconnect in the temporal trends of absolute cases and rates. Disparities remain, and MASLD-related liver cancer continues to surge.\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2024.10.031\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.10.031","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景& 目的成人原发性肝癌的流行病学不断演变,这与代谢性疾病发病率的增加、饮酒量的增加、乙型肝炎(HBV)疫苗接种的进步以及丙型肝炎(HCV)抗病毒治疗有关。不同人群在肝癌治疗和负担方面的差异依然存在。我们评估了 204 个国家和地区从 2010 年到 2021 年的肝癌负担趋势以及各种病因造成的肝癌负担。方法利用《2021 年全球疾病负担研究》的方法框架,我们分析了全球和地区发病率和死亡率的时间趋势以及各种肝病病因造成的肝癌负担。从 2010 年到 2021 年,全球肝癌发病病例和死亡病例分别增加了 26% 和 25%。全球肝癌年龄标准化发病率(ASIRs)和死亡率(ASDRs)有所下降,但美洲和东南亚的发病率和死亡率有所上升。HBV仍然是全球肝癌发病和死亡的主要原因。代谢功能障碍相关性脂肪性肝病(MASLD)是肝癌病因中唯一一个ASIR和ASDR上升的病因。相比之下,酒精相关肝癌的年龄调整发病率和年龄调整死亡率保持稳定,而乙肝病毒和丙肝病毒相关肝癌的年龄调整发病率和年龄调整死亡率则有所下降。人口增长和老龄化导致了所观察到的绝对病例和发病率的时间趋势脱节。差异依然存在,与MASLD相关的肝癌继续激增。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Liver Cancer in 2021: Global Burden of Disease Study

Liver Cancer in 2021: Global Burden of Disease Study

Background & Aims

The epidemiology of adult primary liver cancer continues to evolve, related to the increasing prevalence of metabolic disease, rising alcohol consumption, advancements in vaccination for hepatitis B (HBV), and antiviral therapy for hepatitis C (HCV). Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021.

Methods

Utilizing the methodological framework of the Global Burden of Disease Study 2021, we analyzed global and regional temporal trends in incidence and mortality, and the contributions of various etiologies of liver disease.

Results

In 2021, there were an estimated 529202 incident cases and 483875 deaths related to liver cancer. From 2010 to 2021, global liver cancer incident cases and deaths increased by 26% and 25%, respectively. Global age-standardized incidence rates (ASIRs) and death rates (ASDRs) for liver cancer declined but rose in the Americas and Southeast Asia. HBV remained the dominant cause of global incident liver cancer cases and deaths. Metabolic dysfunction-associated steatotic liver disease (MASLD) was the only etiology of liver cancer with rising ASIRs and ASDRs. By contrast, ASIRs and ASDRs remained stable for alcohol-related liver cancer, and declined for HBV- and HCV-related liver cancer.

Conclusions

While age-adjusted incidence and deaths from liver cancer have started to decline, the absolute number of incident cases and deaths continues to increase. Population growth and aging contribute to the observed disconnect in the temporal trends of absolute cases and rates. Disparities remain, and MASLD-related liver cancer continues to surge.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Hepatology
Journal of Hepatology 医学-胃肠肝病学
CiteScore
46.10
自引率
4.30%
发文量
2325
审稿时长
30 days
期刊介绍: The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信